In the latest trading session, 1.32 million Novavax, Inc (NASDAQ:NVAX) shares changed hands as the company’s beta touched 2.93. With the company’s most recent per share price at $7.18 changed hands at -$0.23 or -3.17% at last look, the market valuation stands at $1.15B. NVAX’s current price is a discount, trading about -232.31% off its 52-week high of $23.86. The share price had its 52-week low at $3.81, which suggests the last value was 46.94% up since then.
Analysts gave the Novavax, Inc (NVAX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended NVAX as a Hold, 10 felt it is a Buy and 0 rated the stock as Underweight. Novavax, Inc’s EPS for the current quarter is expected to be -0.76.
Novavax, Inc (NASDAQ:NVAX) trade information
Instantly NVAX was in red as seen in intraday trades today. With action -13.03%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -10.76%, with the 5-day performance at -13.03% in the red. However, in the 30-day time frame, Novavax, Inc (NASDAQ:NVAX) is -22.18% down.
The consensus price target for the stock as assigned by Wall Street analysts is 22, meaning bulls need an upside of 67.36% from its recent market value. According to analyst projections, NVAX’s forecast low is 14 with 25 as the target high. To hit the forecast high, the stock’s price needs a -248.19% plunge from its current level, while the stock would need to soar -94.99% for it to hit the projected low.
Novavax, Inc (NVAX) estimates and forecasts
Year-over-year growth is forecast to reach -30.37% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 85.47M. 1 analysts are of the opinion that Novavax, Inc’s revenue for the current quarter will be 41.9M. The company’s revenue for the corresponding quarters a year ago was 291.34M and 93.86M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -70.66%. The estimates for the next quarter sales put growth at -55.36%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.55%. The 2025 estimates are for Novavax, Inc earnings to increase by 75.51%.
Novavax, Inc (NASDAQ:NVAX)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.4669% or 11.85 million shares worth $149.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 4.86 shares estimated at $34.86 million under it, the former controlled 3.03% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.56% of the shares, roughly 4.1 shares worth around $29.41 million.
